Finally, blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade, while the combined immunotherapy based on C5a and PD-1 blockade has shown synergistic effects on both lung cancer growth and metastatic progression (Ajona et al., 2017). This evidence concerns the gene C5 and neoplasm.